Xeltis Overview
- Founded
-
2006

- Status
-
Private
- Employees
-
42

- Latest Deal Type
-
Series D2
- Latest Deal Amount
-
$18.3M
- Investors
-
9
Xeltis General Information
Description
Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioabsorbable heart valves and blood vessels designed to allow Endogenous Tissue Restoration (ETR) which is the natural restoration of the complex body part that gets replaced upon implantation, enabling the patient's body to naturally restore a new blood vessel or heart valve through a therapeutic approach.
Contact Information
Website
www.xeltis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
- De Lismortel 31
- 5612 AR Eindhoven
- Netherlands
+31 040 000 0000
Xeltis Timeline
Xeltis Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
13. Later Stage VC (Series D2) | 04-Nov-2022 | $18.3M | 00000 | 000.00 | Completed | Generating Revenue |
12. Secondary Transaction - Private | 26-May-2022 | 00000 | Completed | Generating Revenue | ||
11. Accelerator/Incubator | 21-Dec-2021 | 000.00 | 00000 | Completed | Generating Revenue | |
10. Later Stage VC | 22-Nov-2021 | 000.00 | 00000 | Completed | Generating Revenue | |
9. Later Stage VC (Series D) | 05-Sep-2019 | 000.00 | 00000 | 000.00 | Completed | Clinical Trials - General |
8. Later Stage VC (Series C) | 15-Nov-2017 | 000.00 | 00000 | Completed | Clinical Trials - General | |
7. Later Stage VC (Series B) | 27-Nov-2015 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - General |
6. Later Stage VC (Series B) | 08-Dec-2014 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - General |
5. Later Stage VC (Series A) | 15-Oct-2013 | $5.5M | $14.2M | 000.00 | Completed | Clinical Trials - General |
4. Later Stage VC | 08-May-2012 | $1.72M | $8.71M | 000.00 | Completed | Startup |
Xeltis Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series D2 Preferred | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Series D | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Preferred C1 shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
Preferred B shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Preferred B shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
Preferred B shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Preferred A Shares | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Ordinary shares | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Ordinary shares | 109,300 | $0.982874 | $22.11 | $22.11 | 1x | $22.11 | 1.53% | |
Ordinary shares | 137,600 | $0.982874 | $21.84 | $21.84 | 1x | $21.84 | 1.92% |
Xeltis Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device
Therapeutic Devices
Eindhoven, Netherlands
42
As of 2022
00000
00.00
0000-00-00
00000000000
00000
Xeltis Competitors (6)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Edwards Lifesciences | Corporation | Irvine, CA | 00000 | 000 | 000000000 | 000 |
00 00000000 | Corporation | Singapore, Singapore | 000.00 | 000000000 | 000.00 | |
000000000000 | Private Equity-Backed | Puteaux, France | 000 | 000.00 | 000000000000 | |
000000000 | Corporate Backed or Acquired | Berlin, Germany | 0000 | 000000&0 | ||
00000000 | Formerly VC-backed | Durham, NC | 000 | 00000 | 000000000 | 00000 |
Xeltis Patents
Xeltis Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4110200-A1 | Medical device for anastomosis | Pending | 27-Feb-2020 | 000000000 | |
US-20210267599-A1 | Medical device for anastomosis | Pending | 27-Feb-2020 | 000000000 | 0 |
EP-4076286-A1 | Multi-layered electrospun heart valve leaflets | Pending | 20-Dec-2019 | 0000000000 | |
US-20230010851-A1 | Multi-layered electrospun heart valve leaflets | Pending | 20-Dec-2019 | 0000000000 | |
EP-3989881-A1 | Electrospun heart valves | Pending | 27-Jun-2019 | A61F2/2415 |
Xeltis Executive Team (33)
Xeltis Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Christian Wenger Ph.D | Self | Board Member | 000 0000 |
Clemens Van Blitterswijk Ph.D | EQT Life Sciences | Board Member | 000 0000 |
Diego Braguglia Ph.D | VI Partners | Board Member | 000 0000 |
George Fazio | Xeltis | Chairman | 000 0000 |
Michael Colson | Xeltis | Scientific Advisory Board & Chairman | 000 0000 |
Xeltis Signals
Xeltis Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
China Grand Pharmaceutical and Healthcare Holdings | Corporation | Minority | 000 0000 | 000000 0 | |
EIC Accelerator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
European Investment Bank | Investment Bank | Minority | 000 0000 | 000000 0 | |
Ysios Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
EQT Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 |